Book contents
- Treatment-Related StrokeIncluding Iatrogenic and In-hospital Strokes
- Treatment-Related Stroke
- Copyright page
- Dedication
- Contents
- Contributors
- Preface
- Section I Iatrogenic ischemic strokes: peri- and postoperative strokes
- Section II Iatrogenic ischemic strokes: stroke after endovascular procedures
- Section III Iatrogenic ischemic strokes: other causes
- Section IV Iatrogenic hemorrhagic strokes: thrombolysis-related hemorrhagic strokes
- Section V Iatrogenic hemorrhagic strokes: intracranial bleeding
- Section VI Iatrogenic hemorrhagic strokes: anticoagulation-related intracranial hemorrhage
- Section VII Other uncommon causes of iatrogenic stroke
- Section VIII Cerebral venous thrombosis
- Section IX Medication reversal and restarting in patients with iatrogenic strokes
- Index
- References
Section V - Iatrogenic hemorrhagic strokes: intracranial bleeding
Published online by Cambridge University Press: 20 October 2016
Book contents
- Treatment-Related StrokeIncluding Iatrogenic and In-hospital Strokes
- Treatment-Related Stroke
- Copyright page
- Dedication
- Contents
- Contributors
- Preface
- Section I Iatrogenic ischemic strokes: peri- and postoperative strokes
- Section II Iatrogenic ischemic strokes: stroke after endovascular procedures
- Section III Iatrogenic ischemic strokes: other causes
- Section IV Iatrogenic hemorrhagic strokes: thrombolysis-related hemorrhagic strokes
- Section V Iatrogenic hemorrhagic strokes: intracranial bleeding
- Section VI Iatrogenic hemorrhagic strokes: anticoagulation-related intracranial hemorrhage
- Section VII Other uncommon causes of iatrogenic stroke
- Section VIII Cerebral venous thrombosis
- Section IX Medication reversal and restarting in patients with iatrogenic strokes
- Index
- References
- Type
- Chapter
- Information
- Treatment-Related StrokeIncluding Iatrogenic and In-Hospital Strokes, pp. 169 - 184Publisher: Cambridge University PressPrint publication year: 2016
References
Qureshi, A I, Mendelow, A D, Hanley, D F. Intracerebral haemorrhage. Lancet. 2009; 373:1632–44.
Trialists’ Collaboration. A collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. British Medical Journal. 2002; 324:71–86.
Sudlow, C L M, Warlow, C P; International Stroke Incidence C. Comparable studies of the incidence of stroke and its pathological types: Results from an international collaboration. Stroke. 1997; 28:491–9.
Carolei, A, Marini, C, Di Napoli, M, et al. High stroke incidence in the prospective community-based l’Aquila registry (1994–1998): First year’s results. Stroke. 1997; 28:2500–6.
Dennis, M S. Outcome after brain haemorrhage. Cerebrovascular Diseases. 2003; 16(suppl 1):9–13.
Kothari, R U, Brott, T, Broderick, J P, et al. The ABCs of measuring intracerebral hemorrhage volumes. Stroke. 1996; 27:1304–5.
Broderick, J P, Brott, T G, Duldner, J E, Tomsick, T, Huster, G. Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality. Stroke. 1993; 24:987–93.
Palareti, G, Leali, N, Coccheri, S, et al. Bleeding complications of oral anticoagulant treatment: An inception-cohort, prospective collaborative study (ISCOAT). Lancet. 1996; 348:423–8.
Nicolini, A, Ghirarduzzi, A, Iorio, A, et al. Intracranial bleeding: Epidemiology and relationships with antithrombotic treatment in 241 cerebral hemorrhages in Reggio Emilia. Haematologica. 2002; 87:948–56.
Rosand, J, Eckman, M H, Knudsen, K A, Singer, D E, Greenberg, S M. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Archives of Internal Medicine. 2004; 164:880–4.
Campbell, P G, Sen, A, Yadla, S, Jabbour, P, Jallo, J. Emergency reversal of antiplatelet agents in patients presenting with an intracranial hemorrhage: A clinical review. World Neurosurgery. 2010; 74:279–85.
Cantalapiedra, A, Gutierrez, O, Tortosa, J I, et al. Oral anticoagulant treatment: Risk factors involved in 500 intracranial hemorrhages. Journal of Thrombosis and Thrombolysis. 2006; 22:113–20.
Caso, V, Paciaroni, M, Venti, M, et al. Effect of on-admission antiplatelet treatment on patients with cerebral hemorrhage. Cerebrovascular Diseases. 2007; 24:215–18.
Foerch, C, Sitzer, M, Steinmetz, H, Neumann-Haefelin, T. Pretreatment with antiplatelet agents is not independently associated with unfavorable outcome in intracerebral hemorrhage. Stroke. 2006; 37:2165–7.
Roquer, J, Campello, A R, Gomis, M, et al. Previous antiplatelet therapy is an independent predictor of 30-day mortality after spontaneous supratentorial intracerebral hemorrhage. Journal of Neurology. 2005; 252:412–16.
Sansing, L H, Messe, S R, Cucchiara, B L, et al. Prior antiplatelet use does not affect hemorrhage growth or outcome after ICH. Neurology. 2009; 72:1397–402.
Toyada, K, Okada, Y, Minematsu, K, et al. Antiplatelet therapy contributes to acute deterioration of intracerebral hemorrhage. Neurology. 2005; 65:1000–4.
Akbari, S H, Reynolds, M R, Kadkhodayan, Y, Cross, D T, Moran, C J. Hemorrhagic complications after prasugrel (Effient) therapy for vascular neurointerventional procedures. Journal of Neurointerventional Surgery. 2012.
Broderick, J P, Diringer, M N, Hill, M D, et al. Determinants of intracerebral hemorrhage growth: an exploratory analysis. Stroke. 2007; 38:1072–5.
Lacut, K, Le Gal, G, Seizeur, R, et al. Antiplatelet drug use preceding the onset of intracerebral hemorrhage is associated with increased mortality. Fundamental & Clinical Pharmacology. 2007; 21:327–33.
Roquer, J. Previous antiplatelet treatment and mortality in patients with intracerebral hemorrhage. Stroke. 2007; 38:863.
Sorimachi, T, Fujii, Y, Morita, K, Tanaka, R. Predictors of hematoma enlargement in patients with intracerebral hemorrhage treated with rapid administration of antifibrinolytic agents and strict blood pressure control. Journal of Neurosurgery. 2007; 106:250–4.
Thrift, A G, McNeil, J J, Forbes, A, Donnan, G A. Risk of primary intracerebral haemorrhage associated with aspirin and non-steroidal anti-inflammatory drugs: Case-control study. British Medical Journal. 1999; 318:759–64.
Hart, R G, Tonarelli, S B, Pearce, L A. Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. Stroke. 2005; 36:1588–93.
Hennekens, C. Final report on the aspirin component of the ongoing physicians health study. New England Journal of Medicine. 1989; 321:129–35.
The SALT Collaborative Group. Swedish Aspirin Low-dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet. 1991; 338:1345–19.
He, J, Whelton, P, Vu, B, Klag, M. Aspirin and risk of hemorrhagic stroke. Journal of the American Medical Association. 1998; 280:1930–5.
Sudlow, C. Antithrombotic Treatment: Clinical Evidence. London: BMJ Publishing Group; 2001.
Thrift, A G, McNeil, J J, Forbes, A, Donnan, G A. Risk of primary intracerebral haemorrhage associated with aspirin and non-steroidal anti-inflammatory drugs: Case-control study. British Medical Journal. 1999; 318:759.
Baldi, G, Altomonte, F, Altomonte, M, et al. Intracranial haemorrhage in patients on antithrombotics: Clinical presentation and determinants of outcome in a prospective multicentric study in Italian emergency departments. Cerebrovascular Diseases. 2006; 22:286–93.
Connolly, B J, Pearce, L A, Kurth, T, Kase, C S, Hart, R G. Aspirin therapy and risk of subdural hematoma: Meta-analysis of randomized clinical trials. Journal of Stroke and Cerebrovascular Diseases. 2013.
Hass, W K, Easton, J D, Adams, H P Jr, et al. Ticlopidine Aspirin Stroke Study Group. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. New England Journal of Medicine. 1989; 321:501–7.
Gent, M, Donald Easton, J, Hachinski, V, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet. 1989; 333:1215–20.
Montalescot, G, Wiviott, S D, Braunwald, E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (triton-timi 38): Double-blind, randomised controlled trial. Lancet. 2009; 373:723–31.
Becker, R C, Bassand, J P, Budaj, A, et al. Bleeding complications with the p2y12 receptor antagonists clopidogrel and ticagrelor in the Platelet Inhibition and Patient Outcomes (PLATO) trial. European Heart Journal. 2011; ehr422.
Cordina, S M, Hassan, A E, Ezzeddine, M A. Prevalence and clinical characteristics of intracerebral hemorrhages associated with clopidogrel. Journal of Vascular and Interventional Neurology. 2009; 2:136.
Weber, A A, Braun, M, Hohlfeld, T, et al. Recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers. British Journal of Clinical Pharmacology. 2001; 52:333–6.
Gent, M, Beaumont, D, Blanchard, J, et al. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996; 348:1329–39.
Diener, H-C, Sacco, R L, Yusuf, S, et al. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the prevention regimen for effectively avoiding second strokes (PROFESS) trial: A double-blind, active and placebo-controlled study. Lancet Neurology. 2008; 7:875–84.
Sacco, R L, Diener, H-C, Yusuf, S, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. New England Journal of Medicine. 2008; 359:1238–51.
Campbell, P G, Yadla, S, Sen, A N, Jallo, J, Jabbour, P. Emergency reversal of clopidogrel in the setting of spontaneous intracerebral hemorrhage. World Neurosurgery. 2011; 76:100–4.
Naidech, A M, Bendok, B R, Garg, R K, et al. Reduced platelet activity is associated with more intraventricular hemorrhage. Neurosurgery. 2009; 65:684–8.
Naidech, A M, Bernstein, R A, Levasseur, K, et al. Platelet activity and outcome after intracerebral hemorrhage. Annals of Neurology. 2009; 65:352–6.
Naidech, A M, Jovanovic, B, Liebling, S, et al. Reduced platelet activity is associated with early clot growth and worse 3-month outcome after intracerebral hemorrhage. Stroke. 2009; 40:2398–401.
Berger, P B, Bhatt, D L, Fuster, V, et al. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance (CHARISMA) trial. Circulation. 2010; 121:2575–83.
Diener, H-C, Bogousslavsky, J, Brass, L M, et al. Aspirin and Clopidogrel Compared with Clopidogrel Alone after Recent Ischaemic Stroke or Transient Ischaemic Attack in High-risk Patients (MATCH): Randomised, double-blind, placebo-controlled trial. Lancet. 2004; 364:331–7.
Kennedy, J, Hill, M D, Ryckborst, K J, et al. Fast Assessment of Stroke and Transient Ischaemic Attack to Prevent Early Recurrence (FASTER): A randomised controlled pilot trial. Lancet Neurology. 2007; 6:961–9.
Wang, Y, Wang, Y, Zhao, X, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. New England Journal of Medicine. 2013; 369:11–19.
Johnston, S C, Easton, J D, Farrant, M, et al. Platelet-oriented inhibition in new TIA and minor ischemic stroke (POINT) trial: rationale and design. International Journal of Stroke. 2013; 8:479–83.
Benavente, O R, White, C L, Pearce, L, et al. The Secondary Prevention of Small Subcortical Strokes (SPS3) study. International Journal of Stroke. 2011; 6:164–75.
Chimowitz, M I, Lynn, M J, Derdeyn, C P, et al. Stenting versus aggressive medical therapy for intracranial arterial stenosis. New England Journal of Medicine. 2011; 365:993–1003.
Wong, K S L, Chen, C, Fu, J, et al. Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): A randomised, open-label, blinded-endpoint trial. Lancet Neurology. 2010; 9:489–97.
Wang, Y, Wang, Y, Zhao, X, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. New England Journal of Medicine. 2013; 369:11–19.
Geeganage, C M, Diener, H-C, Algra, A, et al. Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: systematic review and meta-analysis of randomized controlled trials. Stroke. 2012; 43:1058–66.
Markus, H S, Droste, D W, Kaps, M, et al. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using Doppler embolic signal detection: the clopidogrel and aspirin for reduction of emboli in symptomatic carotid stenosis (CARESS) trial. Circulation. 2005; 111:2233–40.
Connolly, S J, Pogue, J, Hart, R G, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. New England Journal of Medicine. 2009; 360:2066–78.
Connolly, S, Pogue, J, Hart, R, et al. Active writing group of the active investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (Active W): A randomised controlled trial. Lancet. 2006; 367:1903–12.
Nurden, A T, Poujol, C, Durrieu-Jais, C, Nurden, P. Platelet glycoprotein IIb/IIIa inhibitors: basic and clinical aspects. Arteriosclerosis, Thrombosis, and Vascular Biology. 1999; 19:2835–40.
The Epic I. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. New England Journal of Medicine. 1994; 330:956–61.
The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. New England Journal of Medicine. 1997; 336:1689–97.
Lincoff, A M, Califf, R M, Anderson, K M, et al. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7e3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. Journal of the American College of Cardiology. 1997; 30:149–56.
Qureshi, A I. Adjunctive use of platelet glycoprotein IIb/IIIa inhibitors for carotid angioplasty and stent placement: Time to say good bye? Journal of Endovascular Therapy. 2003; 10:42–4.
Velat, G J, Burry, M V, Eskioglu, E, et al. The use of abciximab in the treatment of acute cerebral thromboembolic events during neuroendovascular procedures. Surgical Neurology. 2006; 65:352–8.
Deshmukh, V R, Fiorella, D J, Albuquerque, F C, et al. Intra-arterial thrombolysis for acute ischemic stroke: Preliminary experience with platelet glycoprotein IIb/IIIa inhibitors as adjunctive therapy. Neurosurgery. 2005; 56.
Qureshi, A I, Siddiqui, A M, Hanel, R A, et al. Safety of high-dose intravenous eptifibatide as an adjunct to internal carotid artery angioplasty and stent placement: A prospective registry. Neurosurgery. 2004; 54.
Qureshi, A I, Saad, M, Zaidat, O O, et al. Intracerebral hemorrhages associated with neurointerventional procedures using a combination of antithrombotic agents including abciximab. Stroke. 2002; 33:1916–19.
Kellert, L, Hametner, C, Rohde, S, et al. Endovascular stroke therapy tirofiban is associated with risk of fatal intracerebral hemorrhage and poor outcome. Stroke. 2013; 44:1453–5.
Gotoh, F, Tohgi, H, Hirai, S, et al. Cilostazol stroke prevention study: A placebo-controlled double-blind trial for secondary prevention of cerebral infarction. Journal of Stroke and Cerebrovascular Diseases. 2000; 9:147–57.
Goto, S. Cilostazol: Potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. Atherosclerosis Supplements. 2005; 6:3–11.
Gorter, J. Major bleeding during anticoagulation after cerebral ischemia patterns and risk factors. Neurology. 1999; 53:1319.
Smith, E, Rosand, J, Knudsen, K, Hylek, E, Greenberg, S. Leukoaraiosis is associated with warfarin-related hemorrhage following ischemic stroke. Neurology. 2002; 59:193–7.
Werring, D, Coward, L, Losseff, N, Jäger, H, Brown, M. Cerebral microbleeds are common in ischemic stroke but rare in TIA. Neurology. 2005; 65:1914–18.
Vernooij, M, Van Der Lugt, A, Ikram, M, et al. Prevalence and risk factors of cerebral microbleeds: the Rotterdam Scan Study. Neurology. 2008; 70:1208–14.
Greenberg, S M, Eng, J A, Ning, M, Smith, E E, Rosand, J. Hemorrhage burden predicts recurrent intracerebral hemorrhage after lobar hemorrhage. Stroke. 2004; 35:1415–20.
Jeon, S-B, Kang, D-W, Lee, E-M, et al. Initial microbleeds at MR imaging can predict recurrent intracerebral hemorrhage. Journal of Neurology. 2007; 254:508–12.
Vernooij, M W, Haag, M D, van der Lugt, A, et al. Use of antithrombotic drugs and the presence of cerebral microbleeds: The Rotterdam scan study. Archives of Neurology. 2009.
Soo, Y O, Yang, S R, Lam, W W, et al. Risk vs benefit of anti-thrombotic therapy in ischaemic stroke patients with cerebral microbleeds. Journal of Neurology. 2008; 255:1679–86.
Wintzen, A, De Jonge, H, Loeliger, E, Bots, G. The risk of intracerebral hemorrhage during oral anticoagulant treatment: A population study. Annals of Neurology. 1984; 16:553–8.
Greenberg, S M. Cerebral amyloid angiopathy: prospects for clinical diagnosis and treatment. Neurology. 1998; 51:690–4.
Rosand, J, Hylek, E M, O’Donnell, H C, Greenberg, S M. Warfarin-associated hemorrhage and cerebral amyloid angiopathy: a genetic and pathologic study. Neurology. 2000; 55:947–51.
Wong, K, Mok, V, Lam, W, et al. Aspirin-associated intracerebral hemorrhage: clinical and radiologic features. Neurology. 2000; 54:2298–301.
Gregoire, S M, Jäger, H, Yousry, T A, et al. Brain microbleeds as a potential risk factor for antiplatelet-related intracerebral haemorrhage: Hospital-based, case-control study. Journal of Neurology, Neurosurgery & Psychiatry. 2010; 81:679–84.
Buresly, K, Eisenberg, M J, Zhang, X, Pilote, L. Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction. Archives of Internal Medicine. 2005; 165:784.
Dale, J, Myhre, E, Storstein, O, Stormorken, H, Efskind, L. Prevention of arterial thromboembolism with acetylsalicylic acid: A controlled clinical study in patients with aortic ball valves. American Heart Journal. 1977; 94:101–11.
Hansen, M L, Sorensen, R, Clausen, M T, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Archives of Internal Medicine. 2010; 170:1433.
Rodgers, R P, Levin, J. A critical reappraisal of the bleeding time. Semin Thromb Hemost. 1990; 16:1–20.
Yardumian, D A, Mackie, I J, Machin, S J. Laboratory investigation of platelet function: A review of methodology. Journal of Clinical Pathology. 1986; 39:701–12.
Davidson, J F, Colvin, B T, Barrowcliffe, T W, et al. The British Society for Haematology Hemostasis and Thrombosis Task-force. Guidelines on platelet-function testing. Journal of Clinical Pathology. 1988; 41:1322–30.
Seidel, H, Rahman, M M, Scharf, R E. Monitoring of antiplatelet therapy. Current limitations, challenges, and perspectives. Hamostaseologie. 2011; 31:41–51.
Breet, N J, van Werkum, J W, Bouman, H J, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. Journal of the American Medical Association. 2010; 303:754–62.
Sibbing, D, Schulz, S, Braun, S, et al. Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. Journal of Thrombosis and Haemostasis. 2010; 8:250–6.
Godino, C, Mendolicchio, L, Figini, F, et al. Comparison of Verifynow-p2y. Thrombosis Journal. 2009; 7:4.
Jakubowski, J A, Li, Y G, Small, D S, et al. A comparison of the Verifynow p2y12 point-of-care device and light transmission aggregometry to monitor platelet function with prasugrel and clopidogrel: An integrated analysis. Journal of Cardiovascular Pharmacology. 2010; 56:29–37.
Mangiacapra, F, Patti, G, Peace, A, et al. Comparison of platelet reactivity and periprocedural outcomes in patients with versus without diabetes mellitus and treated with clopidogrel and percutaneous coronary intervention. American Journal of Cardiology. 2010; 106:619–23.
Ozben, S, Ozben, B, Tanrikulu, A M, Ozer, F, Ozben, T. Aspirin resistance in patients with acute ischemic stroke. Journal of Neurology. 2011; 258:1979–86.
Paniccia, R, Antonucci, E, Gori, A M, et al. Different methodologies for evaluating the effect of clopidogrel on platelet function in high‐risk coronary artery disease patients. Journal of Thrombosis and Haemostasis. 2007; 5:1839–47.
Paniccia, R, Antonucci, E, Maggini, N, et al. Comparison of methods for monitoring residual platelet reactivity after clopidogrel by point-of-care tests on whole blood in high-risk patients. Thrombosis & Haemostasis. 2010; 104:287.
Altman, R, Scazziota, A, De Lourdes Herrera, M, Gonzalez, C. Recombinant factor VIIa reverses the inhibitory effect of aspirin or aspirin plus clopidogrel on in vitro thrombin generation. Journal of Thrombosis and Haemostasis. 2006; 4:2022–7.
Flordal, P A, Sahlin, S. Use of desmopressin to prevent bleeding complications in patients treated with aspirin. British Journal of Surgery. 1993; 80:723–4.
Gratz, I, Koehler, J, Olsen, D, et al. The effect of desmopressin acetate on postoperative hemorrhage in patients receiving aspirin therapy before coronary artery bypass operations. Journal of Thoracic and Cardiovascular Surgery. 1992; 104:1417–22.
James, R F, Palys, V, Lomboy, J R, Lamm, J R Jr, Simon, S D. The role of anticoagulants, antiplatelet agents, and their reversal strategies in the management of intracerebral hemorrhage. Neurosurgical Focus. 2013; 34:E6.
Gayle, J A, Kaye, A D, Kaye, A M, Shah, R. Anticoagulants: Newer ones, mechanisms, and perioperative updates. Anesthesiology Clinics. 2010; 28:667–79.
Horwitz, P A, Berlin, J A, Sauer, W H, et al. Bleeding risk of platelet glycoprotein IIb/IIIa receptor antagonists in broad-based practice (results from the Society for Cardiac Angiography and Interventions Registry). American Journal of Cardiology. 2003; 91:803–6.
Ducruet, A F, Hickman, Z L, Zacharia, B E, et al. Impact of platelet transfusion on hematoma expansion in patients receiving antiplatelet agents before intracerebral hemorrhage. Neurological Research. 2010; 32:706–10.
Nishijima, D K, Zehtabchi, S, Berrong, J, Legome, E. Utility of platelet transfusion in adult patients with traumatic intracranial hemorrhage and preinjury antiplatelet use: A systematic review. Journal of Trauma and Acute Care Surgery. 2012; 72.
Batchelor, J S, Grayson, A. A meta-analysis to determine the effect on survival of platelet transfusions in patients with either spontaneous or traumatic antiplatelet medication-associated intracranial haemorrhage. BMJ Open. 2012; 2.
de Gans, K, de Haan, R J, Majoie, C B, et al. PATCH: Platelet Transfusion in Cerebral Haemorrhage: Study protocol for a multicentre, randomised, controlled trial. BMC Neurology. 2010; 10:19.
Qureshi, A I. Intracerebral hemorrhage specific intensity of care quality metrics. Neurocritical Care. 2011; 14:291–317.
Baker, R I, Coughlin, P B, Gallus, A S, et al. Warfarin reversal: Consensus guidelines on behalf of the Australasian Society of Thrombosis and Haemostasis. Medical Journal of Australia. 2004; 181:492–7.
Jr. Pollack, C V, Reilly, P A, Eikelboom, J, et al. Idamcizumab for dabigatran reversal. New England Journal of Medicine. 2015; 373:511–20.
Kazui, S, Minematsu, K, Yamamoto, H, Sawada, T, Yamaguchi, T. Predisposing factors to enlargement of spontaneous intracerebral hematoma. Stroke. 1997; 28:2370–5.
Dandapani, B K, Suzuki, S, Kelley, R E, Reyes-Iglesias, Y, Duncan, R C. Relation between blood pressure and outcome in intracerebral hemorrhage. Stroke. 1995; 26:21–4.
Vemmos, K N, Tsivgoulis, G, Spengos, K, et al. Association between 24-h blood pressure monitoring variables and brain oedema in patients with hyperacute stroke. Journal of Hypertension. 2003; 21:2167–73.
Anderson, C S, Huang, Y, Wang, J G, et al. Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT): A randomised pilot trial. Lancet Neurology. 2008; 7:391–9.
Qureshi, A I. Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH). Neurocritical Care. 2007; 6:56–66.
Butcher, K S, Jeerakathil, T, Hill, M, et al. The intracerebral hemorrhage acutely decreasing arterial pressure trial. Stroke. 2013; 44:620–6.
Ropper, A H. Lateral displacement of the brain and level of consciousness in patients with an acute hemispheral mass. New England Journal of Medicine. 1986; 314:953–8.
Vespa, P M, O’Phelan, K, Shah, M, et al. Acute seizures after intracerebral hemorrhage: a factor in progressive midline shift and outcome. Neurology. 2003; 60:1441–6.
Qureshi, A I. Acute hypertensive response in patients with stroke pathophysiology and management. Circulation. 2008; 118:176–87.
Lee, S H, Kim, B J, Bae, H J, et al. Effects of glucose level on early and long-term mortality after intracerebral haemorrhage: The acute brain bleeding analysis study. Diabetologia. 2010; 53:429–34.
Reith, J, Jorgensen, H S, Pedersen, P M, et al. Body temperature in acute stroke: Relation to stroke severity, infarct size, mortality, and outcome. Lancet. 1996; 347:422–5.
Chastre, J, Wolff, M, Fagon, J-Y, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: A randomized trial. Journal of the American Medical Association. 2003; 290:2588–98.
Ogata, T, Yasaka, M, Wakugawa, Y, et al. Deep venous thrombosis after acute intracerebral hemorrhage. Journal of the Neurological Sciences. 2008; 272:83–6.
Boeer, A, Voth, E, Henze, T H, Prange, H W. Early heparin therapy in patients with spontaneous intracerebral haemorrhage. Journal of Neurology, Neurosurgery & Psychiatry. 1991; 54:466–7.
Tetri, S, Hakala, J, Juvela, S, et al. Safety of low-dose subcutaneous enoxaparin for the prevention of venous thromboembolism after primary intracerebral haemorrhage. Thrombosis Research. 2008; 123:206–12.
Misra, U K, Kalita, J, Pandey, S, Mandal, S K, Srivastava, M. A randomized placebo controlled trial of ranitidine versus sucralfate in patients with spontaneous intracerebral hemorrhage for prevention of gastric hemorrhage. Journal of the Neurological Sciences. 2005; 239:5–10.
Eddleston, J M, Pearson, R C, Holland, J, et al. Prospective endoscopic study of stress erosions and ulcers in critically ill adult patients treated with either sucralfate or placebo. Critical Care Medicine. 1994; 22:1949–54.
Finestone, H M, Greene-Finestone, L S, Wilson, E S, Teasell, R W. Prolonged length of stay and reduced functional improvement rate in malnourished stroke rehabilitation patients. Archives of Physical Medicine and Rehabilitation. 1996; 77:340–5.
Qureshi, A I, Suarez, J I, Parekh, P D, Bhardwaj, A. Prediction and timing of tracheostomy in patients with infratentorial lesions requiring mechanical ventilatory support. Critical Care Medicine. 2000; 28:1383–7.
Griffiths, J, Barber, V S, Morgan, L, Young, J D. Systematic review and meta-analysis of studies of the timing of tracheostomy in adult patients undergoing artificial ventilation. British Medical Journal. 2005; 330:1243.
Dennis, M S, Lewis, S C, Warlow, C. Routine oral nutritional supplementation for stroke patients in hospital (food): A multicentre randomised controlled trial. Lancet. 2005; 365:755–63.
Hemphill, J C 3rd, White, D B. Clinical nihilism in neuroemergencies. Emergency Medicine Clinics of North America. 2009; 27:27–37.